British F2G Biotech bags 24m
The European Investment Bank (EIB) has lent antiinfectives company F2G Biotech Ltd 24m for antifungal research and innovation under the InnovFin Infectious Diseases Finance Facility (IDFF).
Sugar replacement slows cancer growth
Researchers at Cancer UK have slowed down tumour growth by simply feeding mice that carry human tumour xenografts with mannose instead of glucose.
Epigenetic drugs can increase tumour malignancy
Researchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.
Mittwoch: Epigenetic drugs can increase tumour malignancy
Researchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.
Forbion leads 40m financing in Inflazome Ltd
Inflammosome inhibitor specialist Inflazome Ltd has raised 40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners.
Boehringer and Epizyme enter US$300m deal
Boehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.
Breakthrough in restless legs syndrome
Researchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome.
SOBI and AstraZeneca in US$2bn+ deal on RSV antibodies
AstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish Orphan Biovitrum AB.
Antibiotic resistance spreading across Europe
Antimicrobial resistance (AMR) has increased by 32% since 2007 in Europe, according to a brand new report.
Liquid biopsy: size matters
A new method developed by Swiss, Danish and British researchers allows to detect hard-to-trace tumour-derived DNA in the blood (or ctDNA).